Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Eiger Biopharma (NQ: EIGR )

11.43 USD -0.43 (-3.63%)
Streaming Delayed Price Updated: 1:25 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Eiger Biopharma

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018
D-LIVR Study: First-Ever Registration Study for Chronic HDV Infection 
From PR Newswire
Eiger Announces Positive Meeting with FDA on Progeria Program
- Company advancing plans to file NDA for Lonafarnib in Progeria 
From PR Newswire
Eiger BioPharmaceuticals to Participate in Investor Conferences
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that members of the Eiger management team will... 
From PR Newswire
45 Biggest Movers From Yesterday
Gainers China Rapid Finance Limited (NYSE: XRF) shares jumped 30.09 percent to close at $2.81 on Thursday after surging 16.13 ... 
Tags UXIN Benzinga Movers & Shakers
From Benzinga
Eiger BioPharmaceuticals Becomes Oversold (EIGR)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 PREVENT study.... 
From PR Newswire
Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three and six months... 
From PR Newswire
Eiger BioPharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO, will present... 
From PR Newswire
Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today first patient enrolled in the Phase 2 LIFT Study... 
From PR Newswire
Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has received the Notice of Allowance... 
From PR Newswire
Oversold Conditions For Eiger BioPharmaceuticals (EIGR)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that an oral presentation from the Phase 2 LOWR... 
From PR Newswire
Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that David Cory, President and CEO, will... 
From PR Newswire
45 Biggest Movers From Yesterday
Gainers Comstock Holding Companies, Inc. (NASDAQ: CHCI) shares climbed 154.95 percent to close at $5.15 on Thursday. ... 
Tags SRRK DERM PBR
From Benzinga
42 Stocks Moving In Thursday's Mid-Day Session
Gainers Comstock Holding Companies, Inc. (NASDAQ: CHCI) shares surged 115.8 percent to $4.3591. Comstock reported conversion ... 
Tags WSTL TRXC TIS
From Benzinga
Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today the... 
From PR Newswire
25 Stocks Moving In Thursday's Pre-Market Session
Gainers Stellar Biotechnologies, Inc. (NASDAQ: SBOT) rose 32 percent to $2.89 in pre-market trading after the company ... 
Tags ZEAL Trading Ideas Pre/Market Outlook
From Benzinga
Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ... 
Tags Benzinga RTRX EIGR
From Benzinga
12 Stocks To Watch For May 24, 2018
Some of the stocks that may grab investor focus today are: Wall Street expects Best Buy Co., Inc. (NYSE: BBY) to report ... 
Tags MDT News GPS
From Benzinga
9 Stocks Moving In Wednesday's After-Hours Session
Gainers Babcock & Wilcox Enterprises Inc (NYSE: BW) shares are up 16 percent after an amended 13D filing from Steel ... 
Tags Movers WSTL Trading Ideas
From Benzinga
Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that... 
From PR Newswire
36 Biggest Movers From Friday
Gainers Quotient Limited (NASDAQ: QTNT) rose 29 percent to close at $6.05 following commencement of EU blood grouping field ... 
Tags OPHC ABEO LIVX
From Benzinga
26 Stocks Moving In Friday's Mid-Day Session
Gainers Bioblast Pharma Ltd. (NASDAQ: ORPN) shares rose 29.6 percent to $3.22. Mannatech, Incorporated (NASDAQ: MTEX) ... 
Tags CARV BLNK RAVN
From Benzinga
24 Stocks Moving In Friday's Pre-Market Session
Gainers Shineco, Inc. (NASDAQ: TYHT) rose 34.7 percent to $2.29 in pre-market trading following Q3 results. Shineco posted Q3 ... 
Tags AMAT Market News ACAD
From Benzinga
Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ... 
Tags CTSO LOXO Top Stories
From Benzinga
48 Biggest Movers From Yesterday
Gainers Carver Bancorp, Inc. (NASDAQ: CARV) shares climbed 201.37 percent to close at $11.00 on Thursday. Eiger ... 
Tags PLCE Oil & Gas Exploration & Production HK
From Benzinga
Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)
- Plans to Seek FDA Guidance for Potential Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) Indication 
From PR Newswire
Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals
FDA Guidance on Lonafarnib Approval for Progeria Sought 
From PR Newswire
Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results
- Hepatitis Delta Virus (HDV) Program Moving into Phase 3 
From PR Newswire
Benzinga's Top Upgrades, Downgrades For May 9, 2018
Top Upgrades Janney Capital upgraded T2 Biosystems, Inc. (NASDAQ: TTOO) from Neutral to Buy. T2 Biosystems shares rose 9.84 ... 
Tags JEC TEN ROL
From Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.